Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 4

Rigel Pharmaceuticals, Inc.

RIGLNASDAQEQUITYCurrent

SEC Filing

Filed Jun 22, 2026Accepted Jun 22, 2026, 4:12 PM EDTCIK 1034842Accession 0000905148-26-003039
Share

Company context

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Current securities

Recent company filings

  1. 4 filingSep 3, 2026
  2. 4 filingSep 3, 2026
  3. SCHEDULE 13G/A filingAug 14, 2026
  4. SCHEDULE 13G/A filingAug 13, 2026
  5. S-8 filingAug 4, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗